Erratum: Glucose transporter 1-mediated glucose uptake is limiting for B-cell acute lymphoblastic leukemia anabolic metabolism and resistance to apoptosis (Cell Death and Disease (2014) 5 (e1470) DOI: 10.1038/cddis.2014.431);Glucose transporter 1-mediated glucose uptake is limiting for B-cell acute lymphoblastic leukemia anabolic metabolism and resistance to apoptosis

Cell Death and Disease

Volumn 5, Issue 10, 2014, Pages

  Liu, T ^a   Kishton, R J ^a   Macintyre, A N ^a   Gerriets, V A ^a   Xiang, H ^a   Liu, X ^b   Abel, E D ^c   Rizzieri, D ^d   Locasale, J W ^b   Rathmell, J C ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Obstetrics Gynecology   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIM PROTEIN; DASATINIB; DEOXYGLUCOSE; GLUCOSE; GLUCOSE TRANSPORTER 1; TAMOXIFEN; APOPTOSIS REGULATORY PROTEIN; BCL-2-LIKE PROTEIN 11; MEMBRANE PROTEIN; ONCOPROTEIN; SLC2A1 PROTEIN, HUMAN;

ACUTE LYMPHOBLASTIC LEUKEMIA; AEROBIC GLYCOLYSIS; AEROBIC METABOLISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CATABOLISM; CELL PROLIFERATION; CHEMOSENSITIZATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; GENE DELETION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; METABOLIC INHIBITION; METABOLIC REGULATION; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; DISEASE COURSE; DRUG EFFECTS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; TUMOR CELL LINE;

AEROBIOSIS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYGLUCOSE; DISEASE PROGRESSION; GENE DELETION; GLUCOSE; GLUCOSE TRANSPORTER TYPE 1; GLYCOLYSIS; HUMANS; MEMBRANE PROTEINS; METABOLIC NETWORKS AND PATHWAYS; MOLECULAR TARGETED THERAPY; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTO-ONCOGENE PROTEINS;

EID: 84926369919     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.493     Document Type: Erratum

References (44)

1. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029-1033.
2. Moorman AV, Harrison CJ, Buck GA, Richards SM, Secker-Walker LM, Martineau M et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood 2007; 109: 3189-3197.
3. Caro P, Kishan AU, Norberg E, Stanley IA, Chapuy B, Ficarro SB et al. Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma. Cancer Cell 2012; 22: 547-560.
4. Wieman HL, Wofford JA, Rathmell JC. Cytokine stimulation promotes glucose uptake via phosphatidylinositol-3 kinase/Akt regulation of Glut1 activity and trafficking. Mol Biol Cell 2007; 18: 1437-1446.
5. Barnes K, McIntosh E, Whetton AD, Daley GQ, Bentley J, Baldwin SA. Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation. Oncogene 2005; 24: 3257-3267.
6. Cilloni D, Saglio G. Molecular pathways: BCR-ABL. Clin Cancer Res 2012; 18: 930-937.
7. Kharas MG, Janes MR, Scarfone VM, Lilly MB, Knight ZA, Shokat KM et al. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. J Clin Invest 2008; 118: 3038-3050.
8. Mason EF, Zhao Y, Goraksha-Hicks P, Coloff JL, Gannon H, Jones SN et al. Aerobic glycolysis suppresses p53 activity to provide selective protection from apoptosis upon loss of growth signals or inhibition of BCR-Abl. Cancer Res 2010; 70: 8066-8076.
9. Vander Heiden MG. Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov 2011; 10: 671-684.
10. El Mjiyad N, Caro-Maldonado A, Ramirez-Peinado S, Munoz-Pinedo C. Sugar-free approaches to cancer cell killing. Oncogene 2011; 30: 253-264.
11. Brunelle JK, Letai A. Control of mitochondrial apoptosis by the Bcl-2 family. J Cell Sci 2009; 122: 437-441.
12. Zhao Y, Coloff JL, Ferguson EC, Jacobs SR, Cui K, Rathmell JC. Glucose metabolism attenuates p53 and puma-dependent cell death upon growth factor deprivation. J Biol Chem 2008; 283: 36344-36353.
13. Coloff JL, Macintyre AN, Nichols AG, Liu T, Gallo CA, Plas DR et al. Akt-dependent glucose metabolism promotes Mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition. Cancer Res 2011; 71: 5204-5213.
14. Coloff JL, Mason EF, Altman BJ, Gerriets VA, Liu T, Nichols AN et al. Akt requires glucose metabolism to suppress puma expression and prevent apoptosis of leukemic T cells. J Biol Chem 2011; 286: 5921-5933.
15. Caro-Maldonado A, Tait SW, Ramirez-Peinado S, Ricci JE, Fabregat I, Green DR et al. Glucose deprivation induces an atypical form of apoptosis mediated by caspase-8 in Bax-, Bak-deficient cells. Cell Death Differ 2010; 17: 1335-1344.
16. Palorini R, Cammarata FP, Balestrieri C, Monestiroli A, Vasso M, Gelfi C et al. Glucose starvation induces cell death in K-ras-transformed cells by interfering with the hexosamine biosynthesis pathway and activating the unfolded protein response. Cell Death Dis 2013; 4: e732.
17. Thorens B, Mueckler M. Glucose transporters in the 21st Century. Am J Physiol Endocrinol Metab 2010; 298: E141-E145.
18. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008; 7: 11-20.
19. Caro-Maldonado A, Wang R, Nichols AG, Kuraoka M, Milasta S, Sun LD et al. Metabolic reprogramming is required for antibody production that is suppressed in anergic but exaggerated in chronically BAFF-exposed B cells. J Immunol 2014; 192: 3626-3636.
20. Macintyre AN, Gerriets VA, Nichols AG, Michalek RD, Rudolph MC, Deoliveira D et al. The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function. Cell Metab 2014; 20: 61-72.
21. Jacobs SR, Herman CE, Maciver NJ, Wofford JA, Wieman HL, Hammen JJ et al. Glucose uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent and independent pathways. J Immunol 2008; 180: 4476-4486.
22. Liu X, Ser Z, Locasale JW. Development and quantitative evaluation of a high-resolution metabolomics technology. Anal Chem 2014; 86: 2175-2184.
23. DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA 2007; 104: 19345-19350.
24. Puthalakath H, O'Reilly LA, Gunn P, Lee L, Kelly PN, Huntington ND et al. ER stress triggers apoptosis by activating BH3-only protein Bim. Cell 2007; 129: 1337-1349.
25. Vander Heiden MG. Exploiting tumor metabolism: challenges for clinical translation. J Clin Invest 2013; 123: 3648-3651.
26. Maratou E, Dimitriadis G, Kollias A, Boutati E, Lambadiari V, Mitrou P et al. Glucose transporter expression on the plasma membrane of resting and activated white blood cells. Eur J Clin Invest 2007; 37: 282-290.
27. Oleszczak B, Szablewski L, Pliszka M. The effect of hyperglycemia and hypoglycemia on glucose transport and expression of glucose transporters in human lymphocytes B and T: an in vitro study. Diabetes Res Clin Pract 2012; 96: 170-178.
28. Everts B, Amiel E, van der Windt GJ, Freitas TC, Chott R, Yarasheski KE et al. Commitment to glycolysis sustains survival of NO-producing inflammatory dendritic cells. Blood 2012; 120: 1422-1431.
29. Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 2005; 18: 283-293.
30. Chakrabarti A, Chen AW, Varner JD. A review of the mammalian unfolded protein response. Biotechnol Bioeng 2011; 108: 2777-2793.
31. Ghosh AP, Klocke BJ, Ballestas ME, Roth KA. CHOP potentially co-operates with FOXO3a in neuronal cells to regulate PUMA and BIM expression in response to ER stress. PLoS One 2012; 7: e39586.
32. Young CD, Lewis AS, Rudolph MC, Ruehle MD, Jackman MR, Yun UJ et al. Modulation of glucose transporter 1 (GLUT1) expression levels alters mouse mammary tumor cell growth in vitro and in vivo. PLoS One 2011; 6: e23205.
33. Israelsen WJ, Dayton TL, Davidson SM, Fiske BP, Hosios AM, Bellinger G et al. PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell 2013; 155: 397-409.
34. Yalcin A, Telang S, Clem B, Chesney J. Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer. Exp Mol Pathol 2009; 86: 174-179.
35. Xie H, Hanai J, Ren JG, Kats L, Burgess K, Bhargava P et al. Targeting lactate dehydrogenase-a inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor-initiating cells. Cell Metab 2014; 19: 795-809.
36. Gras D, Roze E, Caillet S, Meneret A, Doummar D, Billette de Villemeur T et al. GLUT1 deficiency syndrome: an update. Rev Neurol 2014; 170: 91-99.
37. Heilig CW, Saunders T, Brosius FC 3rd, Moley K, Heilig K, Baggs R et al. Glucose transporter-1-deficient mice exhibit impaired development and deformities that are similar to diabetic embryopathy. Proc Natl Acad Sci USA 2003; 100: 15613-15618.
38. Liu Y, Cao Y, Zhang W, Bergmeier S, Qian Y, Akbar H et al. A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. Mol Cancer Ther 2012; 11: 1672-1682.
39. Kraus M, Malenke E, Gogel J, Muller H, Ruckrich T, Overkleeft H et al. Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis. Mol Cancer Ther 2008; 7:1940-1948.
40. Tuccinardi T, Granchi C, Iegre J, Paterni I, Bertini S, Macchia M et al. Oxime-based inhibitors of glucose transporter 1 displaying antiproliferative effects in cancer cells. Bioorg Med Chem Lett 2013; 23: 6923-6927.
41. Wood TE, Dalili S, Simpson CD, Hurren R, Mao X, Saiz FS et al. A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death. Mol Cancer Ther 2008; 7: 3546-3555.
42. Hresko RC, Hruz PW. HIV protease inhibitors act as competitive inhibitors of the cytoplasmic glucose binding site of GLUTs with differing affinities for GLUT1 and GLUT4. PLoS One 2011; 6: e25237.
43. Xia J,Mandal R, Sinelnikov IV, Broadhurst D,Wishart DS. MetaboAnalyst 2.0-a comprehensive server for metabolomic data analysis. Nucleic Acids Res 2012; 40: W127-W133.
44. Wang RN, Dillon CP, Shi LZ, Milasta S, Carter RFinkelstein D et al. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity 2011; 35: 871-882.